bluebird bio (BLUE) Competitors $0.37 -0.04 (-10.19%) (As of 11:57 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BLUE vs. VALN, ARTV, ITOS, CCCC, ATYR, TNYA, LXEO, KYTX, OCGN, and TCRXShould you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Valneva (VALN), Artiva Biotherapeutics (ARTV), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), Atyr PHARMA (ATYR), Tenaya Therapeutics (TNYA), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Ocugen (OCGN), and TScan Therapeutics (TCRX). These companies are all part of the "biological products, except diagnostic" industry. bluebird bio vs. Valneva Artiva Biotherapeutics iTeos Therapeutics C4 Therapeutics Atyr PHARMA Tenaya Therapeutics Lexeo Therapeutics Kyverna Therapeutics Ocugen TScan Therapeutics Valneva (NASDAQ:VALN) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership. Which has more volatility and risk, VALN or BLUE? Valneva has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Does the MarketBeat Community prefer VALN or BLUE? bluebird bio received 1007 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 71.12% of users gave bluebird bio an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% bluebird bioOutperform Votes103971.12% Underperform Votes42228.88% Do analysts recommend VALN or BLUE? Valneva presently has a consensus price target of $18.50, suggesting a potential upside of 378.04%. bluebird bio has a consensus price target of $3.03, suggesting a potential upside of 625.25%. Given bluebird bio's higher probable upside, analysts plainly believe bluebird bio is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00bluebird bio 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation and earnings, VALN or BLUE? Valneva has higher revenue and earnings than bluebird bio. Valneva is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$165.52M1.90-$109.78M-$0.13-29.77bluebird bio$29.50M2.75-$211.91M-$1.87-0.22 Is VALN or BLUE more profitable? Valneva has a net margin of -4.35% compared to bluebird bio's net margin of -565.74%. Valneva's return on equity of -3.93% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% bluebird bio -565.74%-322.46%-53.17% Does the media favor VALN or BLUE? In the previous week, bluebird bio had 2 more articles in the media than Valneva. MarketBeat recorded 8 mentions for bluebird bio and 6 mentions for Valneva. Valneva's average media sentiment score of 0.56 beat bluebird bio's score of -0.16 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bluebird bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in VALN or BLUE? 11.4% of Valneva shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 1.4% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryValneva beats bluebird bio on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLUE vs. The Competition Export to ExcelMetricbluebird bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.10M$3.09B$5.24B$8.93BDividend YieldN/A1.84%5.23%4.05%P/E Ratio-0.2218.5990.1913.75Price / Sales2.75296.281,469.6281.34Price / CashN/A175.8435.2535.09Price / Book-13.903.545.695.49Net Income-$211.91M-$41.68M$117.66M$224.81M7 Day Performance12.73%6.36%2.86%1.98%1 Month Performance-10.49%5.32%1.79%9.78%1 Year Performance-90.21%38.03%35.90%29.97% bluebird bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLUEbluebird bio3.3579 of 5 stars$0.37-10.2%$3.03+707.5%-90.2%$72.84M$29.50M-0.20323Short Interest ↓VALNValneva2.6317 of 5 stars$3.89-4.0%$18.50+375.6%-66.4%$316.05M$158.54M-29.62700Gap DownHigh Trading VolumeARTVArtiva BiotherapeuticsN/A$12.87+0.7%$21.25+65.1%N/A$312.61MN/A0.0081Positive NewsITOSiTeos Therapeutics3.833 of 5 stars$8.50-0.6%$31.50+270.6%-13.6%$310.54M$35M-2.7190Positive NewsCCCCC4 Therapeutics1.6128 of 5 stars$4.36-4.2%$10.00+129.4%+168.8%$307.77M$33.67M-2.68150Short Interest ↑ATYRAtyr PHARMA2.7222 of 5 stars$3.52-0.3%$19.25+446.9%N/A$295.48M$235,000.00-3.7656Analyst ForecastShort Interest ↑TNYATenaya Therapeutics3.8751 of 5 stars$3.57flat$17.33+385.5%+81.7%$282.82MN/A-2.56110High Trading VolumeLXEOLexeo Therapeutics2.6338 of 5 stars$8.53+3.6%$23.80+179.0%-45.2%$282.05M$650,000.00-2.6058Upcoming EarningsPositive NewsKYTXKyverna Therapeutics2.2564 of 5 stars$6.43+11.4%$25.71+299.9%N/A$277.60M$7.03M0.0096Gap UpOCGNOcugen1.4842 of 5 stars$0.93-5.0%$5.67+507.5%+138.3%$271.74M$4.70M-5.4665TCRXTScan Therapeutics2.0212 of 5 stars$4.70-1.5%$12.00+155.3%-25.2%$250.84M$9.36M-4.41100Positive News Related Companies and Tools Related Companies Valneva Competitors Artiva Biotherapeutics Competitors iTeos Therapeutics Competitors C4 Therapeutics Competitors Atyr PHARMA Competitors Tenaya Therapeutics Competitors Lexeo Therapeutics Competitors Kyverna Therapeutics Competitors Ocugen Competitors TScan Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLUE) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
